Evidence map›Paper›PMID 42305197›Full record

ArticleACS medicinal chemistry letters2026

Structure-Based Search for Novel Creatine Transporter Inhibitors.

Dorota Stary, Ali El-Kasaby, Danila Boytsov, Paula Zaręba, Justyna Godyń, Mateusz Maszczyk, Zuzanna Rzepka, Dorota Wrześniok, Christoph Sotriffer, Walter Sandtner and 2 more

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Dorota StaryDepartment of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Cracow, Poland.
Ali El-KasabyInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, 1090, Austria.
Danila BoytsovInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, 1090, Austria.
Paula ZarębaDepartment of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Cracow, Poland.ORCID https://orcid.org/0000-0002-5037-6183
Justyna GodyńDepartment of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Cracow, Poland.ORCID https://orcid.org/0000-0002-0295-2772
Mateusz MaszczykCentre of Innovation and Research on Prohealthy and Safe Food, University of Agriculture in Krakow, Balicka 104, 30-149 Krakow, Poland.
Zuzanna RzepkaDepartment of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Jagiellońska 4, 41-200 Sosnowiec, Poland.
Dorota WrześniokDepartment of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, Jagiellońska 4, 41-200 Sosnowiec, Poland.
Christoph SotrifferInstitute of Pharmacy and Food Chemistry, University of Würzburg, Am Hubland 97074, Würzburg, Germany.
Walter SandtnerInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, 1090, Austria.
Michael FreissmuthInstitute of Pharmacology, Center of Physiology and Pharmacology, Medical University of Vienna, Vienna, 1090, Austria.
Marek BajdaDepartment of Physicochemical Drug Analysis, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Cracow, Poland.ORCID https://orcid.org/0000-0001-6032-0354

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Creatine transporter 1 (CT1, SLC6A8) regulates cellular energy levels. Mutations in CT1 cause severe neurological disorders, whereas CT1 overexpression has been associated with cancer progression. Rational development of CT1 inhibitors has been limited by the absence of structural data. Here, we constructed homology models of CT1 representing distinct transport states and integrated them into a structure-based virtual screening workflow. From this approach, 16 top-ranked compounds were tested

Indexed as

creatine transporterdockingmolecular dynamicsstructure-based drug designvirtual screening

Identifiers

PMID42305197
PMCPMC13266637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.